Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 36Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 4Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Adenocarcinoma 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Prostate Cancer Metastatic 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-Resistant Prostate Cancer 1Mesothelioma, Malignant 1Melanoma 1

Interventions

Cisplatin 20Radiotherapy 16Paclitaxel 14Carboplatin 12pembrolizumab 11Drug Therapy 11tislelizumab 10Fluorouracil 8Neoadjuvant Therapy 7130-nm albumin-bound paclitaxel 7sintilimab 5Esophagectomy 5toripalimab 4Tegafur 4TP protocol 4Nivolumab 4Irinotecan 4Immunotherapy 4spartalizumab 3S 1 (combination) 3Oxaliplatin 3Leucovorin 3Itraconazole 3Docetaxel 3Albumin-Bound Paclitaxel 3nimotuzumab 2apatinib 2Taxes 2Radiotherapy, Intensity-Modulated 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Squamous Cell Carcinoma × enzalutamide × Clear all
NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
862 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡